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for intracranial pressure reduction after traumatic
brain injury (the Eurotherm3235Trial): outcome
of the pilot phase of the trial
Peter J D Andrews1*, Louise H Sinclair1, Bridget Harris1, Melissa J Baldwin2, Claire G Battison1, Jonathan K J Rhodes1,
Gordon Murray3, Daniel De Backer4 and On behalf of the Eurotherm3235Trial collaboratorsAbstract
Background: Clinical trials in traumatic brain injury (TBI) are challenging. Previous trials of complex interventions were
conducted in high-income countries, reported long lead times for site setup and low screened-to-recruitment rates.
In this report we evaluate the internal pilot phase of an international, multicentre TBI trial of a complex intervention to
assess: design and implementation of an online case report form; feasibility of recruitment (sites and patients);
feasibility and effectiveness of delivery of the protocol.
Methods: All aspects of the pilot phase of the trial were conducted as for the main trial. The pilot phase had oversight
by independent Steering and Data Monitoring committees.
Results: Forty sites across 12 countries gained ethical approval. Thirty seven of 40 sites were initiated for recruitment.
Of these, 29 had screened patients and 21 randomized at least one patient. Lead times to ethics approval (6.8 weeks),
hospital approval (18 weeks), interest to set up (61 weeks), set up to screening (11 weeks), and set up to randomization
(31.6 weeks) are comparable with other international trials. Sixteen per cent of screened patients were eligible. We
found 88% compliance rate with trial protocol.
Conclusion: The pilot data demonstrated good feasibility for this large international multicentre randomized
controlled trial of hypothermia to control intracranial pressure. The sample size was reduced to 600 patients because of
homogeneity of the patient group and we showed an optimized cooling intervention could be delivered.
Trial registration: Current Controlled Trials: ISRCTN34555414.
Keywords: Traumatic brain injury, Therapeutic hypothermia, Randomized controlled trial, FeasibilityBackground
The pattern of severe traumatic brain injury (TBI) is
changing globally with the incidence increasing rapidly
in low- and middle-income countries as a result of
increased motor vehicle use [1]. Previous trials of complex
interventions in TBI patients have been conducted in
high-income countries such as Europe and the US.
However, the increasing cost and administrative burden
of conducting large clinical trials has forced researchers* Correspondence: p.andrews@ed.ac.uk
1Department of Anaesthesia and Pain Management, University of Edinburgh,
Edinburgh, UK
Full list of author information is available at the end of the article
© 2013 Andrews et al.; licensee BioMed Centr
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reproduction in any medium, provided the orto conduct trials in low-income countries where costs
are lower and the potential patient pool is higher [2]. If
treatments for TBI patients are to be successful, future
trials of any intervention that may improve outcome after
TBI should be tested in high-, middle- and low-income
countries to assess generalizability [2].
A report published by the European Forum for Good
Clinical Practice [3] aimed to evaluate the impact of
Directive 2001/20/EC, the Clinical Trial Directive
throughout Europe. Results of the survey showed a
30% extended timeline to protocol approval as a result
of increased workload for Ethics Committees, less
harmonization of the ethical review process, variableal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the added complexity of the trial Sponsor contracting
insurance for participating hospitals. A proposal to amend
the Directive is currently with the European Parliament in
an attempt to streamline and improve practices throughout
the European Union.
Clinical trials in severe TBI are therefore challenging
due to global incidence, administrative burden associated
with large clinical trials and the heterogeneity of the
condition. Previous trials of TBI patients have reported
long lead times for site setup/approvals and low screened-
to-recruitment rates [4]. A balance must therefore be
achieved between our current understanding of the mech-
anisms of action of the intervention being evaluated and
maximizing recruitment by using broad inclusion criteria.
The National Institute of Neurological Disorders and
Stroke determined in October 2007 that recruitment of
heterogeneous TBI patients to clinical trials was a major
impediment to success [5]. Clinical trials using broad
inclusion criteria could, however, use a statistical analysis
plan incorporating a pre-specified covariate adjustment to
reduce the effects of heterogeneity [6].
Current treatments for TBI emphasize restoring and
maintaining adequate brain perfusion, surgically evacuating
large hematomas where necessary, and preventing or
promptly treating edema [7]. Brain swelling can be moni-
tored by measuring intracranial pressure (ICP) and, in most
centers, ICP is used to guide treatments and to monitor
their success [8]. The initiation of hypothermia following
severe TBI is used in this context despite few supporting
data. However, the need for resuscitation and computerized
tomography imaging to confirm the diagnosis in pa-
tients with TBI are factors which delay intervention
with temperature reduction strategies [9].
The use of hypothermia to improve outcomes in patients
with acute brain injury is not a new idea. However, the
evidence to date of efficacy from prophylactic neuro-
protection trials in patients with TBI is modest [7,10].
The Eurotherm3235Trial is an international, multicentre,
randomized controlled trial investigating if therapeutic
hypothermia (32 to 35°C) used to manage raised ICP
following severe TBI leads to improved outcome. No trial
has previously tested this treatment paradigm.
Study objectives
The Eurotherm3235Trial aims to answer the research
question: does titrated hypothermia to reduce raised ICP
after TBI improve outcome at 6 months?
In this report we evaluate data collected during the
internal pilot phase (January 2009 to August 2011) to
assess the following criteria: design and implementation
of an online electronic case report form (eCRF) for
screening, randomisation and data collection; feasibility
of recruitment (sites and patients); patient eligibility -previous observational studies had predicted that 50%
of all TBI patients would be eligible [11]; and feasibility
of the protocol, in particular the effectiveness of delivery
of the cooling protocol.
Methods
The trial protocol was developed by the Edinburgh trial
team in collaboration with an international advisory board
that included key experts in this field of research, experi-
enced trialists, specialist nurses and statisticians [12].
Full details of the trial protocol have been published
previously [12]. In summary, this is a pragmatic, multi-
centre randomized controlled trial examining the effects
of hypothermia (32 to 35°C), titrated to reduce ICP to
below 20 mmHg, on morbidity and mortality 6 months
after TBI (extended Glasgow Outcome Scale (GOSE)).
The study aimed to recruit 1,800 patients over 41 months.
Enrolment started in November 2009.
The main ethical issue with this trial is that patients
are adults with incapacity. We have complied with the
devolved nations legal requirements and have favorable
ethical opinion from all (09/MRE00/34; Scotland A re-
search Ethics Committee). Similar arrangements have
been satisfied in another 13 countries. Due to their
incapacitated state, it is not be possible to obtain written
consent directly from potential participants. Consent is
therefore sought from each eligible patient’s nearest
relative or another person designated to give consent on
the patient’s behalf.
Participants are randomized to either standard care
or standard care with titrated therapeutic hypothermia.
Hypothermia is initiated with 20 to 30 ml/kg intravenous
refrigerated 0.9% sodium chloride and maintained using
each site’s usual cooling technique. There is a guideline for
detection and treatment of shivering in the intervention
group. Hypothermia is maintained for at least 48 hours
in the treatment group and continued for as long as is
necessary to maintain ICP <20 mmHg. Intracranial hyper-
tension is defined as an ICP >20 mmHg in accordance
with the Brain Trauma Foundation Guidelines, 2007 [7].
The Eurotherm3235Trial cooling protocol aims to lower
core temperature by the minimum required to control
ICP <20 mmHg, within the limits of 32 to 35°C. If a
patient’s ICP is not controlled on cooling to 35°C, core
temperature is lowered in 0.5°C increments until ICP is <20
mmHg, to a minimum temperature of 32°C. Therapeutic
hypothermia is maintained for a minimum of 48 hours.
All aspects of the pilot phase of the trial were conducted
as for the main trial. The pilot phase of the trial had over-
sight by an independent Data Safety Monitoring Board
(DSMB) who work according to a charter (based upon
DAMOCLES principles) signed by all three members
(Peter Suter, Ian Ford and Kathy Rowan). They report to
an independent Trial Steering Committee and recommend
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charter allows for stopping if there is overwhelming
evidence of benefit or harm (this or another trial) but
no other interim analysis is planned. The funder (European
Society of Intensive Care Medicine) appointed a “Research,
Scientific and Financial Committee” providing further
oversight.
Results
Design and implementation
Systems for trial screening, randomization and data
management were developed between January 2009
and June 2009. The first patients were randomized in
Edinburgh between November 2009 and February 2010,
testing the protocol and the paper case record form.
Thereafter the online randomization service (minimization
with a random element) and electronic data collection
database were introduced and validated. Recruitment using
this system started in July 2010. Up to the end of August
2011, 416 patients were screened and 67 randomized to
the trial.
In keeping with a pragmatic trial design, the protocol
and data collection were not burdensome. We collected
hourly data on ICP management and core temperature.
This allowed assessment of whether sites were able to
manage therapeutic hypothermia according to the protocol,
including controlled rewarming, and monitor the manage-
ment of the control group. Crossovers from standard care
(control group) to hypothermia were recorded.
Feasibility of recruitment
During the pilot phase of the trial, 40 sites across 12
countries gained ethical approval (sites per country):
Scotland (3), England (11), Northern Ireland (1), Belgium
(8), Ireland (1), Italy (4), Germany (2), Greece (6), Estonia
(1), Hungary (1), Russia (1) and India (1). Ethical applica-
tions were also submitted for a further 9 sites: Brazil (3),
Italy (1), Portugal (1) and Spain (4).
Thirty seven of the 40 sites with ethical approval were
initiated for recruitment. Of these, 29 had screened
patients and 21 randomized at least one patient during
the pilot phase.
Across the 37 initiated sites, 416 patients were logged
on the eCRF database. Of these, 67 were randomized.
The average time from set up to screening was 11 weeks
and the time from screening to first randomized patient
was 20 weeks. Follow-up for 6 month outcome during
the pilot phase was 100%. Table 1 shows site set up times
during the pilot phase of the Eurotherm3235Trial.
Patient eligibility
Sixteen per cent of screened TBI patients with ICP mon-
itoring were eligible. The Eurotherm3235Trial inclusion
criteria are tighter than most previous trials and the pilotshows they have been effective at recruitment of a
homogenous group of TBI patients with brain swelling
(Table 2). The most common reasons for exclusion were:
ICP less than 20 mmHg, ‘other’ reason, age over 65 years
and more than 72 hours from injury (Table 3).
Feasibility of protocol
Assessment of delivery of cooling showed that, of 34
patients randomized to hypothermia, the average time to
reach target temperature was 4 hours (range 1 to 12
hours). Patients remained within the target range of 32 to
35°C for an average of 86 hours (range 5 to 153 hours).
One patient did not consistently achieve hypothermia
(≤35°C) and four patients (12%) did not receive the mini-
mum 48 hours of hypothermia therapy. The temperature
of eight patients (24%) overshot the lower target limit
of <32°C within the first 3 days of hypothermia therapy
with the temperature of one patient recorded at 30°C
because of problems with the cooling device used. In
summary, we found an 88% compliance rate with the trial
protocol for therapeutic hypothermia.
Two out of 33 patients crossed over from the control to
the hypothermia group. In one, the reason was a clinician
decision based on the patient’s condition. In the other, it
was uncertainty of the trial team in randomizing their first
patient. There were seven serious or severe adverse events
(Table 4), all unrelated to the intervention. It should be
noted that death is not unexpected in this patient cohort
and a mortality of 30% is usual [10,13,14].
One of the objectives set out in the research contract
between ESICM and the University of Edinburgh was to
seek funding from another source. We are grateful to the
National Institute for Health Research, Health Technology
Assessment Programme for funding the full trial. There-
fore, the new funder is a UK statutory funding agency.
Discussion
The pilot phase of the Eurotherm3235Trial ran from
January 2009 until August 2011, with the aims of assessing
the design and implementation of data collection systems,
recruitment and protocol feasibility in the first approxi-
mate 50 patients. During this period, 67 patients were
actually randomized. The information gained from the
pilot has informed refinement and improvement of the
trial with regard to management, patient eligibility and
trial size.
Trial management
Based on the invaluable experience obtained from the
pilot, a significant number of measures have been put in
place to ensure compliance with the trial protocol through
improved support of the trial sites. Study site initiation,
access to support and feedback have all been refined.
Table 1 Site set up times during the pilot phase of the Eurotherm3235Trial
Average time
taken per country
Time to ethics
approval (weeks)
Time to hospital
approval (weeks)
Total time from
interest to set up (weeks)
Time from set up
to screening (weeks)
Time from set up
to randomization (weeks)
UK (15 sites) 8.5 13.3 42.0 6 30.9
Belgium (8 sites) 15.6 14.8 38.0 16 51.0
Estonia (1 site) 5 4 84 6 9
Germany (1 site) 5 8 56 - -
Greece (5 sites) 4.0 7.2 43.0 11 12.8
Hungary (1 site) 4 14 48 7 27
India (1 site) 2.0 13.0 104.0 7 -
Ireland (1 site) 7 50 60 18 30.0
Italy (3 sites) 10.5 27.0 77.0 4 13
Russia (1 site) 6 29 64 20 79
All centers 6.8 18.0 61.6 11 31.6
Table 3 Reasons for exclusion during the pilot phase of
the Eurotherm3235Trial
Reason for exclusion Number
of patients
Percentage
ICP <20 mmHg 138 40
Other reason*
(including decompressive craniectomy)
46 13
Age of patient 42 12
> 72 hours from initial head injury 41 12
Unlikely to survive 24 hours 20 6
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Chief Investigator presentation on DVD and print-outs
of all trial related documentation (including a user guide
for the eCRF). These are delivered by courier prior to
their initiation web-meeting. All UK sites have received
a site initiation visit by one of the Trial Managers. In
most cases, non-UK sites undertake an initiation meeting
with one of the Trial Managers by web conference using
an online ‘Meeting Room’ set up by our IT department.
In rare circumstances a site visit will be conducted if
specifically asked for by the investigator at the site (for
example, because of language difficulties). This has reduced
the carbon footprint of the trial significantly.
After set up, weekly emails are sent to all database
users to inform them of any patients randomized during
the week. A member of the trial team is also available in
the trial office to support the sites, answering phone
calls/queries and a 24-hour helpline is now available.
This is held by a member of the trial team on an on-call
basis, the number is on the trial website.
Each time a patient is randomized, the Trial Manager
responsible for the site will contact the local teamTable 2 Marshall classification for abnormalities seen in
computerized tomography scan of the brain
N %
Total number of 67 100
patients randomized
Missing 1 1.4
Diffuse Axonal Injury, grade I 0 0.0
Diffuse Axonal Injury, grade II 10 14.9
Diffuse Axonal Injury, grade III 12 17.9
Diffuse Axonal Injury, grade IV 5 7.4
Evacuated mass lesion 21 31.3
Non-evacuated mass lesion 18 29personally soon after randomization to thank them for
randomizing the patient and offer support and advice if
required at any time. Four weeks after randomization, all
data in the core eCRF forms (day 1 to 7 forms, Modified
Oxford Handicap scale and follow-up forms) are checked
for missing data or errors in the eCRF by the Trial
Manager responsible for the site. At this time queries
are raised and feedback provided to the local team.
When the forms have been completed satisfactorily they
are frozen in the eCRF by the Data Manager.Patient receiving induced hypothermia 12 4
Administration of barbiturate infusion 12 3
Temperature <34.0°C at hospital admission 11 3
No relative consent 7 2
Open traumatic head injury 8 2
No cooling device 5 1
Core temperature <36.0°C at randomization 4 1
Normal CT scan 2 1
Pregnancy 1 0
Total 349 100
*The category other includes decompressive crainiotomy (largest group),
enrolled in another trial, no research staff available, multiple trauma, no
relatives available, no permanent address, severe burns. CT computerized
tomography, ICP intracranial pressure.
Table 4 Serious adverse events (SAE)
1. Hospitalization Bleeding - defined as a new haemorrhage requiring
2 units of packed red cells
Unrelated
2. Hospitalization Bleeding - defined as a new hemorrhage requiring
2 units of packed red cells
Unrelated
3. Life threatening Cerebral perfusion pressure <50 mmHg for 15 minutes Unrelated
4. Death Cardiovascular instability - systolic blood pressure
<90 mmHg for 30 minutes
Unrelated
5. Life threatening and persistent of significant
disability or incapacity
Cerebral perfusion pressure <50 mmHg for 15 minutes Unrelated
6. Death Cerebral perfusion pressure <50 mmHg for 15 minutes Unrelated
7. Life threatening Cerebral perfusion pressure <50 mmHg for 15 minutes Unrelated
Each line describes an SAE reported during the pilot phase of the Eurotherm3235Trial, and each SAE is classified according to International Conference on
Harmonisation, Good Clinical Practice (http://www.ich.org/).
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whether the site has collected the data and if there are
any issues which need to be resolved or require further
training. Some sites have been unsure how to complete
the forms in the eCRF for their first patient; therefore,
by receiving feedback from the Trial Manager, they learn
how to use the eCRF for their subsequent patients. This
has improved data quality within the eCRF.
An annual Investigator Meeting is held in the autumn
each year and all recruiting teams are invited to attend.
This coincides with a large European meeting that
many investigators already attend. A Eurotherm3235Trial
Newsletter is produced by the trial team every 2 months
and is uploaded to the trial website (http://www.
eurotherm3235trial.eu/project/index.phtml). This gives
information on recruitment, new sites, conference presen-
tations and important trial updates. The newsletter link is
sent by email to all sites that have registered interest along
with all initiated sites.
Patient eligibility
During the internal pilot, 416 patients with ICP monitoring
were screened across the 37 trial sites. Of these, 67
(16%) fulfilled the requirements for randomization. During
protocol development, the predicted ratio of screened to
eligible patients for the Eurotherm3235Trial internal pilot
was derived from an observational study that recruited
201 patients managed in “good” sites. These data led
us to believe that 50% of all ICP monitored patients
would be eligible for recruitment, that is develop ICP >20
mmHg despite simple measures, often described as “stage
I” treatments [11].
Two of the most frequent reasons for exclusion from
the trial were age over 65 years and more than 72 hours
from injury (Table 2). As a result of this analysis,
recruiting sites and all database users were surveyed
and asked if they would be prepared to randomize older
patients and those more than 72 hours from injury.
Following a majority positive response, we submitted aprotocol amendment to every ethics committee involved
in the trial to remove the upper age limit for inclusion
(allowing the clinician at each site to triage patients) and
increase the time from injury from 72 hours to 10 days.
This change was implemented in January 2012.
Trial size
As a result of the internal pilot the sample size for the
full trial was reduced to 600 patients. Two factors
underpinned this decision: the homogeneity of the patient
group - unlike most previous trials all patients had
evidence of brain swelling (raised ICP); and we showed an
optimised cooling intervention could be delivered, which
meant that the meta-analysis by Peterson and colleagues
[10] was the most relevant for the power calculation,
rather than the median estimate of effect of six meta-
analyses on which our original power calculation was
based [12].
The heterogeneity of TBI is considered one of the
principal barriers to finding effective therapeutic inter-
ventions. The Eurotherm3235Trial inclusion criteria are
tighter than most previous trials and have been effective
at recruitment of a more homogenous group of TBI
patients with brain swelling. This is potentially the
subgroup of TBI patients most likely to benefit from
titrated hypothermia [15-17]. The cooling intervention in
this trial is optimized by rapidly inducing hypothermia
using 20 to 30 ml/kg refrigerated 0.9% sodium chloride
and is subsequently managed as suggested by meta-analysis
[10,18]. Thus all patients receive the same ICP manage-
ment without barbiturate infusion throughout the trial
period, hypothermia is maintained for a minimum of 48
hours, and rewarming is slow and controlled (1°C/4
hours). The pilot phase has confirmed that we can deliver
this cooling protocol and in a less heterogeneous group of
TBI patients (that is, only those with brain swelling).
The most relevant recent systematic review is there-
fore that by Peterson and colleagues [10], which found
an overall trend towards 25% improved outcome with
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41.8% favorable outcome, hypothermia versus control,
respectively; relative risk (RR) 1.25; 95% confidence
interval (CI) 0.96 to 1.62). In the subset of trials in which
hypothermia was continued for >48 hours the effect on
outcome was greater (RR 1.91; 95% CI 1.28 to 2.85)
reaching statistical significance. When ICP was managed
without barbiturate infusions, hypothermia was also
associated with a statistically significant improvement
in outcome (RR 1.79; 95% CI 1.27 to 2.52). Similarly,
hypothermia was also associated with a trend to a 20%
reduction in mortality, overall (24.8% versus 28.6%
mortality, hypothermia versus control, respectively; RR
0.80; 95% CI 0.59 to 1.09). Mortality was reduced in the
subset of studies in which hypothermia was continued
for >48 hours (RR 0.51; 95% CI 0.33 to 0.79) or when
ICP was managed without barbiturate infusion (RR 0.58;
95% CI 0.40 to 0.85).
With a conventional dichotomous analysis of the GOSE,
comparing the proportions of patients with an unfavorable
outcome in the two groups, a 600 patient trial has 81%
power at the 5% significance level (two-sided) to detect an
absolute reduction of 12% (60% reducing to 48%). There is
87% power to detect an absolute reduction of 13%
(60% reducing to 47%). This is conservative compared
with the results of the systematic review by Peterson
and colleagues [10] in which optimized therapeutic
cooling was associated with an absolute reduction in
the proportion of patients with unfavorable outcome of
26% [10]. Furthermore, using an ordinal analysis of the
GOSE together with covariate adjustment there is the
potential to increase the statistical efficiency of the
analysis. If we achieve the efficiency gains suggested by
simulations run by the IMPACT investigators [19] and
demonstrated in a reanalysis of the CRASH trial [20],
then a trial of 600 patients would have equivalent
power to a trial of 1,000 patients. This would give 80%
power at the 5% significance level (two-sided) to detect an
absolute reduction of 9% (60% reducing to 51%).
By way of comparison “The Prophylactic Hypothermia
Trial to Lessen Traumatic Brain Injury (POLAR-RCT)”
[21] aims to recruit 500 patients in Australasia to detect
a 15% absolute reduction in unfavorable outcome (GOSE
at 6 months. This is the only concurrent large trial of
hypothermia in TBI, which will answer a different but
complementary research question (does prophylactic early
hypothermia improve outcome after traumatic brain
injury?) to the Eurotherm3235Trial, which is testing ti-
trated hypothermia to reduce ICP and the effect that may
have on outcome.
Conclusion
TBI remains a significant cause of morbidity and mortality
in the world. The options to manage raised ICP remainlimited and each are associated with significant risk.
Therapeutic hypothermia is already used in many centers
around the world as an option in the management of
patients with severe TBI and therefore it is essential to
confidently confirm or refute outcome benefit, rather
than merely palliation of intracranial hypertension. In
the Eurotherm3235Trial pilot we have demonstrated
that we can effectively manage a large international
multicenter randomized controlled trial of hypothermia
(32 to 35°C) to control ICP. Site initiation has proceeded
well, online randomization and data collection are
established and the cooling protocol can be delivered.
Crucially, the pilot has demonstrated recruitment of a
homogeneous patient group and allowed a robust estimate
of sample size. This has been important in helping to
achieve support from the NHS National Institute for
Health Research Health Technology Assessment Program
which will fund the trial to completion in 2016. As of
now (20 March 2013) over 1,256 patients have been
screened and 210 have been randomized (http://www.
eurotherm3235trial.eu).
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